Skip to main content

Table 3 Clinical outcomes

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Response Assessment

Vaccine N = 10

DD + Vaccine N = 7

All N = 17

PR

1 (10 %)

0

1 (6 %)

SD

4 (40 %)

4 (57 %)

8 (47 %)

PD

5 (50 %)

3 (43 %)

8 (47 %)

Time to Progression

4.4 months

4.9 months

4.6 months

  1. DD denileukin diftitox, PD progressive disease, PR partial response, SD stable disease